Eli Lilly
Page 3 of 7
NewslettersEli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
By Sheryl EstradaSeptember 10, 2024
NewslettersIn this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By Lydia BelangerAugust 5, 2024
By Erika FryAugust 2, 2024
FinanceSwiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
HealthPharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
FeaturesOzempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
CommentaryAlzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By Anne E. WhiteJuly 2, 2024
HealthFake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
By Matthew Perrone and The Associated PressJune 11, 2024
RetailNestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By Sasha RogelbergMay 21, 2024
RetailDenmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By Naomi Kresge and BloombergMay 2, 2024
HealthFDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By Tom Murphy, Matthew Perrone and The Associated PressMarch 8, 2024
LifestyleNovo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy
By Prarthana PrakashMarch 8, 2024
Most Popular
